Issue Date: April 16, 2012
Amgen Will Buy Peptide Firm Kai
Amgen is paying $315 million for Kai Pharmaceuticals, a privately held biotech company developing peptide therapeutics. The deal adds to a string of purchases intended to bolster the big biotech firm’s pipeline and technology portfolio.
The centerpiece of the latest acquisition is KAI-4169, a therapeutic peptide for the treatment of hyperparathyroidism in people undergoing dialysis for chronic kidney disease. An intravenous version of KAI-4169, a calcium-sensing receptor agonist, is poised to enter Phase III trials, . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society